PT1544299E - Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular - Google Patents

Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular Download PDF

Info

Publication number
PT1544299E
PT1544299E PT05001328T PT05001328T PT1544299E PT 1544299 E PT1544299 E PT 1544299E PT 05001328 T PT05001328 T PT 05001328T PT 05001328 T PT05001328 T PT 05001328T PT 1544299 E PT1544299 E PT 1544299E
Authority
PT
Portugal
Prior art keywords
treatment
eye disorders
vegf receptor
vascular permeability
disorders characterized
Prior art date
Application number
PT05001328T
Other languages
English (en)
Portuguese (pt)
Inventor
Nicholas J Papadopoulos
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1544299(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT1544299E publication Critical patent/PT1544299E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
PT05001328T 1999-06-08 2000-05-23 Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular PT1544299E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08

Publications (1)

Publication Number Publication Date
PT1544299E true PT1544299E (pt) 2009-03-18

Family

ID=22480568

Family Applications (2)

Application Number Title Priority Date Filing Date
PT05001328T PT1544299E (pt) 1999-06-08 2000-05-23 Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular
PT00932721T PT1183353E (pt) 1999-06-08 2000-05-23 Polipeptidos quimericos modificados com propriedades farmacocineticas melhoradas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT00932721T PT1183353E (pt) 1999-06-08 2000-05-23 Polipeptidos quimericos modificados com propriedades farmacocineticas melhoradas

Country Status (32)

Country Link
EP (2) EP1183353B1 (show.php)
JP (2) JP4723140B2 (show.php)
KR (1) KR100659477B1 (show.php)
CN (3) CN100523187C (show.php)
AT (2) ATE293164T1 (show.php)
AU (2) AU779303B2 (show.php)
BE (1) BE2013C029I2 (show.php)
BR (2) BRPI0011407B8 (show.php)
CA (1) CA2376379C (show.php)
CY (2) CY1108883T1 (show.php)
CZ (2) CZ303656B6 (show.php)
DE (2) DE60041159D1 (show.php)
DK (2) DK1544299T3 (show.php)
ES (2) ES2319305T3 (show.php)
FR (1) FR13C0028I2 (show.php)
HR (1) HRP20010908B1 (show.php)
HU (3) HU229156B1 (show.php)
IL (3) IL146890A0 (show.php)
LT (1) LTC1183353I2 (show.php)
LU (1) LU92195I2 (show.php)
ME (2) ME00024B (show.php)
MX (1) MXPA01012630A (show.php)
NO (4) NO330775B1 (show.php)
NZ (1) NZ515913A (show.php)
PL (1) PL208247B1 (show.php)
PT (2) PT1544299E (show.php)
RS (1) RS50073B (show.php)
RU (1) RU2265661C2 (show.php)
SK (1) SK287332B6 (show.php)
UA (1) UA74146C2 (show.php)
WO (1) WO2000075319A1 (show.php)
ZA (1) ZA200110068B (show.php)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
DE60219419T2 (de) 2001-01-19 2007-08-16 Ludwig Institute For Cancer Research Flt4 (vegfr-3) als ein ziel für krebsdarstellung und anti-krebs-behandlung
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
DE60336341D1 (de) 2002-05-04 2011-04-21 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
DK1608685T3 (da) * 2003-03-28 2007-06-11 Regeneron Pharma VEGF antagonister til behandlingen af diabetes
ES2831031T3 (es) * 2003-05-16 2021-06-07 Acorda Therapeutics Inc Proteínas de fusión para el tratamiento del CNS
JP2007532094A (ja) 2003-05-16 2007-11-15 アコーダ セラピューティクス、インク． Ｃｎｓ治療用のプロテオグリカン分解変異体
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP1626989A2 (en) * 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) * 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
CA2534197A1 (en) * 2003-08-06 2005-02-24 Thomas Jefferson University Use of a vegf antagonist in combination with radiation therapy
US8226941B2 (en) 2004-05-18 2012-07-24 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
EP1767546B1 (en) 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CA2567686A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
WO2006009809A2 (en) * 2004-06-18 2006-01-26 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
WO2006015297A2 (en) * 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type i diabetes by blocking vegf-mediated activity
WO2006031689A2 (en) 2004-09-13 2006-03-23 Genzyme Corporation Multimeric constructs
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
LT2586459T (lt) 2005-03-25 2017-09-25 Regeneron Pharmaceuticals, Inc. Vegf antagonisto kompozicijos
ES2393748T3 (es) 2005-09-26 2012-12-27 Acorda Therapeutics, Inc. Composiciones y métodos de uso de condroitinasa ABCI mutantes
NZ568739A (en) † 2005-12-16 2010-09-30 Regeneron Pharma Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CN104434770A (zh) 2006-06-16 2015-03-25 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
CA3086902C (en) 2006-10-10 2021-11-09 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
CA2742241C (en) 2008-11-03 2019-12-10 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
WO2011047383A1 (en) 2009-10-16 2011-04-21 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
EP3327032A1 (en) 2010-08-06 2018-05-30 Genzyme Corporation Vegf antagonist compositions and uses thereof
EP2662385A4 (en) * 2011-01-07 2015-11-11 Chugai Pharmaceutical Co Ltd METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES
JP2014503555A (ja) 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
JP6138815B2 (ja) 2011-12-01 2017-05-31 エーピー バイオサイエンシーズ， インコーポレイテッド 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
DK2846836T3 (da) 2012-05-07 2019-11-11 Allergan Inc Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
MX368730B (es) 2013-02-18 2019-10-14 Vegenics Pty Ltd Moleculas que unen ligando y usos de las mismas.
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
PT3065761T (pt) 2013-11-05 2020-02-21 Allergan Inc Método de tratamento de condições oculares com um darpin anti-vegf
CA2947456C (en) 2014-05-12 2023-03-14 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
JP6685276B2 (ja) 2014-07-18 2020-04-22 サノフイＳａｎｏｆｉ 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
EP3985023A1 (en) 2014-12-11 2022-04-20 Bayer Healthcare LLC Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202440904A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（二）
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR20180083377A (ko) 2015-11-18 2018-07-20 포르미콘 아게 Vegf 안타고니스트를 함유하는 사전충전형 플라스틱 주사기
WO2017087871A1 (en) 2015-11-18 2017-05-26 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
MX2018006092A (es) 2015-11-18 2019-01-31 Formycon Ag Envase farmacéutico precargado que comprende una formulación líquida de un antagonista del vegf.
EP3377101A4 (en) * 2015-11-19 2019-08-07 Zhuhai Tairuishang Biopharm Ltd. VEGF BINDING METHODS AND COMPOSITIONS
FI3384049T3 (fi) 2015-12-03 2023-09-25 Regeneron Pharma Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
US20190300607A1 (en) 2016-10-12 2019-10-03 Daiichi Sankyo Company, Limited Composition containing anti-robo4 antibody and other agents
WO2018094316A1 (en) 2016-11-21 2018-05-24 Just Biotherapeutics, Inc. Aflibercept formulations and uses thereof
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CN111344410B (zh) 2017-08-17 2023-09-15 济世易为生物有限公司 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
BR112020010674A2 (pt) * 2017-11-27 2020-11-10 4D Molecular Therapeutics Inc. capsídeos de variante de vírus adeno-associado e uso para inibir a angiogênese
ES2927049T3 (es) 2017-11-30 2022-11-02 Regeneron Pharma Uso de un antagonista del VEGF para tratar trastornos oculares angiogénicos
WO2019118187A1 (en) * 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Devices and systems for chromatography column bed support management and related methods
DK3743091T3 (da) 2018-01-26 2025-01-06 Univ California Fremgangsmåder og sammensætninger til behandling af angiogene lidelser under anvendelse af anti-vegf-midler
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
PT4364724T (pt) 2018-05-10 2025-12-16 Regeneron Pharma Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
EP3969564A1 (en) 2019-05-16 2022-03-23 Formycon AG Method for reducing methionine oxidation in recombinant proteins
AU2020343242A1 (en) 2019-09-03 2022-03-10 Amgen Inc. Injection device for drug delivery and packaging for the injection device
CA3150482A1 (en) 2019-09-16 2021-03-25 Amgen Inc. Method for external sterilization of drug delivery device
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
JP2023505216A (ja) 2019-12-06 2023-02-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆミニトラップおよびそれらの使用方法
EP3906303A1 (en) * 2019-12-06 2021-11-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
CA3167020A1 (en) 2020-02-24 2021-09-02 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
US20250002557A1 (en) 2021-11-24 2025-01-02 Suzhou Light Ferry Biomed. Co., Ltd Multi-specific ligand-binding molecules and applications thereof
EP4549455A1 (en) * 2022-08-02 2025-05-07 Panolos Bioscience, Inc. Modified fusion protein and use thereof
KR20250065646A (ko) 2022-09-16 2025-05-13 치루 파머수티컬 컴퍼니 리미티드 안정적인 고농도 자가완충식 약물 조성물
WO2025033876A1 (ko) * 2023-08-04 2025-02-13 주식회사 파노로스바이오사이언스 변형된 융합 단백질과 scFv의 결합체 및 이의 용도
WO2025213011A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Method of assessing stopper movement in a drug delivery device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
NO2022060I1 (no) 2022-12-21
DK1183353T3 (da) 2005-08-08
JP5273746B2 (ja) 2013-08-28
MEP3208A (xx) 2010-02-10
HU229156B1 (en) 2013-09-30
BR0011407A (pt) 2002-04-02
PL208247B1 (pl) 2011-04-29
NO20016036D0 (no) 2001-12-10
CZ303656B6 (cs) 2013-01-30
CA2376379A1 (en) 2000-12-14
NO2013010I2 (no) 2013-05-15
CN101433715A (zh) 2009-05-20
HK1043388A1 (en) 2002-09-13
HRP20010908A2 (en) 2005-04-30
AU5040400A (en) 2000-12-28
SK287332B6 (sk) 2010-07-07
JP4723140B2 (ja) 2011-07-13
RS50073B (sr) 2009-01-22
BRPI0011407B8 (pt) 2021-05-25
NO20016036L (no) 2002-02-08
CN103349781B (zh) 2015-04-01
NO330775B1 (no) 2011-07-11
RU2265661C2 (ru) 2005-12-10
NO2013010I1 (no) 2013-06-17
LU92195I2 (fr) 2013-07-15
LTC1183353I2 (lt) 2023-02-27
NZ515913A (en) 2004-01-30
EP1183353A1 (en) 2002-03-06
ZA200110068B (en) 2002-12-06
BE2013C029I2 (show.php) 2019-03-06
ES2237429T3 (es) 2005-08-01
HUS1300052I1 (hu) 2016-08-29
IL146890A (en) 2008-07-08
EP1183353B1 (en) 2005-04-13
HRP20010908B1 (en) 2006-05-31
JP2003501089A (ja) 2003-01-14
HUP0201515A2 (en) 2002-08-28
CN103349781A (zh) 2013-10-16
JP2011024595A (ja) 2011-02-10
CN100523187C (zh) 2009-08-05
FR13C0028I2 (fr) 2014-05-16
CZ302689B6 (cs) 2011-09-07
WO2000075319A1 (en) 2000-12-14
IL146890A0 (en) 2002-08-14
CN101433715B (zh) 2013-04-17
SK17522001A3 (sk) 2003-04-01
NO20100656L (no) 2002-02-08
YU86901A (sh) 2004-05-12
HU230159B1 (hu) 2015-09-28
DE60019415T2 (de) 2006-03-09
AU2005201365B2 (en) 2007-08-09
HK1132653A1 (en) 2010-03-05
CZ20014387A3 (cs) 2002-10-16
KR100659477B1 (ko) 2006-12-20
KR20020019070A (ko) 2002-03-09
ES2319305T3 (es) 2009-05-06
PT1183353E (pt) 2005-06-30
MXPA01012630A (es) 2002-07-22
IL190234A0 (en) 2008-11-03
HK1185798A1 (en) 2014-02-28
HUP0201515A3 (en) 2004-12-28
EP1544299A1 (en) 2005-06-22
UA74146C2 (uk) 2005-11-15
PL352246A1 (en) 2003-08-11
CY2013019I1 (el) 2015-11-04
ATE417928T1 (de) 2009-01-15
AU779303B2 (en) 2005-01-13
FR13C0028I1 (fr) 2013-06-14
DK1544299T3 (da) 2009-03-23
ME00024B (me) 2010-02-10
BRPI0011407B1 (pt) 2018-09-25
EP1544299B1 (en) 2008-12-17
CY2013019I2 (el) 2015-11-04
CY1108883T1 (el) 2014-07-02
CN1369009A (zh) 2002-09-11
LTPA2013009I1 (lt) 2013-06-25
NO332559B1 (no) 2012-10-29
ATE293164T1 (de) 2005-04-15
AU2005201365A1 (en) 2005-04-28
DE60041159D1 (de) 2009-01-29
DE60019415D1 (de) 2005-05-19
CA2376379C (en) 2007-08-07

Similar Documents

Publication Publication Date Title
PT1544299E (pt) Quimeras do receptor do fcev para o tratamento de doenças dos olhos caracterizadas por permeabilidade vascular
IL146082A0 (en) Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
AU6110301A (en) Diagnostics and therapeutics for macular degeneration-related disorders
WO2003039404A3 (en) Methods for treating ocular neovascular diseases
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
FR12C0004I1 (show.php)
WO2000062790A8 (en) Soluble tumor necrosis factor receptor treatment of medical disorders
ATE424211T1 (de) Therapeutische verwendung von sapogeninen
HU0104018D0 (en) Use of antagonists of nr2b subtype of nmda receptor for medical treatment
AU4128901A (en) Colored visco-elastic composition
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
DK2407536T3 (da) Adp-ribosyltransferase-fusionsvariantproteiner
ATE404199T1 (de) Verwendung von naloxon zur behandlung von essstörungen
DE60008151D1 (de) 5-ht2 agonisten als mittel zur kontrolle des augeninnendrucks und zur behandlung von glaukom
ZA200309642B (en) Benzo (G) quinoline derivatives for treating glaucoma and myopia.
WO2006091666A3 (en) Methods and compositions for treating conditions of the eye
FR2816633B1 (fr) Methode de criblage d'agents susceptibles de traiter l'obesite